Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
IBER.WS
IBER.WS was delisted on the 15th of February, 2023.
38 hedge funds and large institutions have $2.19M invested in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
5% more capital invested
Capital invested by funds: $2.08M → $2.19M (+$109K)
3% more funds holding
Funds holding: 37 → 38 (+1)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$34.5K |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$25.5K |
| 3 |
Calamos Advisors
Naperville,
Illinois
|
+$13.4K |
| 4 |
CAC
Cowen and Company
New York
|
+$3.5K |
| 5 |
EFI
EHP Funds Inc
Toronto,
Canada
|
+$1.64K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$5.35K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.51K |
| 3 |
Capstone Investment Advisors
New York
|
-$1K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$53 |
IBER.WS Hedge Fund Activity: Q3 2022 in Review
38 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) for Q3 2022, worth a combined $2.19M — up 5.2% from $2.08M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new IBER.WS positions and 2 closed out — a net gain of 1 holder — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Magnetar Financial, adding an estimated $34.5K. The largest seller was Shaolin Capital Management, cutting an estimated $5.35K.
- 38 institutional investors held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) as of Q3 2022, up from 37 in Q2 2022.
- Funds reported $2.19M of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share stock for Q3 2022, up 5.2% quarter-over-quarter.
- 3 funds opened new Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share positions in Q3 2022 and 2 closed out, a net change of +1 holder.
- The largest Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share buyer in Q3 2022 was Magnetar Financial, an estimated $34.5K added.
- The largest Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share seller in Q3 2022 was Shaolin Capital Management, an estimated $5.35K sold.
Based on aggregated 13F filings for Q3 2022.